Laboratory research demonstrates that FOXO4-DRI's selectivity stems from exploiting fundamental differences between senescent and healthy cell biology, particularly the paradoxical state where senescent cells are primed for apoptosis but protected by specific survival mechanisms
News provided by Ro Apr 09, 2026, 07:15 ET Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s
While high-protein foods should always be your first stop, when they aren't enough, Pratt says protein powder can help fill the gap
These things can lead to swelling
Supply-chain shortages for specific Mounjaro pen strengths have occurred intermittently since launch
The semaglutide versus tirzepatide comparison helps you understand the efficacy differences between the two medications